Key result
Telmisartan did not prevent high altitude-induced arterial stiffening, with aortic pulse wave velocity increasing from 7.41 m/s at sea level to 8.52 m/s at 5400 m (P<0.0001) across both groups.
Why the study?
Does telmisartan prevent arterial stiffening induced by acute and prolonged exposure to high altitude in healthy subjects?
Population
47 healthy subjects (mean age ~40 years, 14 women) exposed to high altitude (up to 5400 m).
Comparison
Telmisartan vs Placebo
Design
RCT, randomized, double-blind
Follow-up
2 weeks at 5400 m
Authors
Loading...
Telmisartan has no role against altitude-induced stiffening; confirms RAAS-independent mechanisms in hypoxic vascular responses.
RCT (n=47)
Double-blind
randomized
Does telmisartan prevent arterial stiffening induced by acute and prolonged exposure to high altitude in healthy subjects?
Inhibition of the renin-angiotensin-aldosterone system with telmisartan does not prevent the arterial stiffening and reduced subendocardial oxygen supply/demand index induced by high altitude hypoxia.
Revera et al. (2017) conducted an RCT in Healthy subjects exposed to high altitude hypoxia (n=47). Telmisartan vs. Placebo was evaluated on Hemodynamic changes (aortic pulse wave velocity and subendocardial oxygen supply/demand index) during acute and prolonged exposure to 5400-m altitude. Telmisartan did not prevent high altitude-induced arterial stiffening, with aortic pulse wave velocity increasing from 7.41 m/s at sea level to 8.52 m/s at 5400 m (P<0.0001) across both groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: